Carbamylated low-density lipoprotein attenuates glucose uptake via a nitric oxide-mediated pathway in rat L6 skeletal muscle cells

Choi,Hye‑Jung; Lee,Kyoung  Jae; Hwang,Eun  Ah; Mun,Kyo‑Cheol; Ha,Eunyoung

doi:10.3892/mmr.2015.3481

Carbamylated low-density lipoprotein attenuates glucose uptake via a nitric oxide-mediated pathway in rat L6 skeletal muscle cells

Authors:
- Hye‑Jung Choi
- Kyoung Jae Lee
- Eun Ah Hwang
- Kyo‑Cheol Mun
- Eunyoung Ha
View Affiliations

Affiliations: Department of Biochemistry and Pain Research Center, School of Medicine, Keimyung University, Daegu 704‑701, Republic of Korea, Department of Orthopedic Surgery, Keimyung University, Dongsan Medical Center, Daegu 700‑712, Republic of Korea, Department of Internal Medicine, Dongsan Kidney Institute, Keimyung University, Dongsan Medical Center, Daegu 700‑712, Republic of Korea
Published online on: March 13, 2015 https://doi.org/10.3892/mmr.2015.3481
Pages: 1342-1346

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carbamylation is a cyanate‑mediated posttranslational modification. We previously reported that carbamylated low‑density lipoprotein (cLDL) increases reactive oxygen species and apoptosis via a lectin‑like oxidized LDL receptor mediated pathway in human umbilical vein endothelial cells. A recent study reported an association between cLDL and type 2 diabetes mellitus (T2DM). In the current study, the effects of cLDL on glucose transport were explored in skeletal muscle cells. The effect of cLDL on glucose uptake, glucose transporter 4 (GLUT4) translocation, and signaling pathway were examined in cultured rat L6 muscle cells using 2‑deoxyglucose uptake, immunofluorescence staining and western blot analysis. The quantity of nitric oxide (NO) was evaluated by the Griess reaction. The effect of native LDL (nLDL) from patients with chronic renal failure (CRF‑nLDL) on glucose uptake was also determined. It was observed that cLDL significantly attenuated glucose uptake and GLUT4 translocation to the membrane, which was mediated via the increase in inducible nitric oxide synthase (iNOS)‑induced NO production. Tyrosine nitration of the insulin receptor substrate‑1 (IRS‑1) was increased. It was demonstrated that CRF‑nLDL markedly reduced glucose uptake compared with nLDL from healthy subjects. Collectively, these findings indicate that cLDL, alone, attenuates glucose uptake via NO-mediated tyrosine nitration of IRS‑1 in L6 rat muscle cells and suggests the possibility that cLDL is involved in the pathogenesis of T2DM.

View Figures

View References

1	Ha E: Cyanate attenuates insulin secretion in cultured pancreatic β cells. Mol Med Rep. 5:1461–1464. 2012.PubMed/NCBI
2	Ok E, Basnakian AG, Apostolov EO, et al: Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int. 68:173–178. 2005. View Article : Google Scholar : PubMed/NCBI
3	Abe T, Isaka Y, Imamura R, et al: Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating eryth-ropoiesis. Cell Transplant. 21:571–580. 2012. View Article : Google Scholar
4	Tang Z, Sun X, Shi Q, et al: Beneficial effects of carbamylated erythropoietin against oxygen-glucose deprivation/reperfusion-induced astrocyte swelling: proposed molecular mechanisms of action. Neurosci Lett. 530:23–28. 2012. View Article : Google Scholar : PubMed/NCBI
5	Jaisson S, Delevallée-Forte C, Touré F, et al: Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett. 581:1509–1513. 2007. View Article : Google Scholar : PubMed/NCBI
6	Son JN, Lho Y, Shin S, et al: Carbamylated low-density lipoprotein increases reactive oxygen species (ROS) and apoptosis via lectin-like oxidized LDL receptor (LOX-1) mediated pathway in human umbilical vein endothelial cells. Int J Cardiol. 146:428–430. 2011. View Article : Google Scholar
7	Hörkkö S, Huttunen K, Kervinen K, et al: Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest. 24:105–113. 1994. View Article : Google Scholar : PubMed/NCBI
8	Kraus LM and Kraus AP Jr: Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl. 78:S102–S107. 2001. View Article : Google Scholar : PubMed/NCBI
9	Wang Z, Nicholls SJ, Rodriguez ER, et al: Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 13:1176–1184. 2007. View Article : Google Scholar : PubMed/NCBI
10	Heilman K, Zilmer M, Zilmer K, et al: Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Diabetes Res Clin Pract. 84:168–173. 2009. View Article : Google Scholar : PubMed/NCBI
11	Wiersma JJ, Meuwese MC, van Miert JN, et al: Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase. Med Sci Monit. 14:CR406–CR410. 2008.PubMed/NCBI
12	Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 414:821–827. 2001. View Article : Google Scholar : PubMed/NCBI
13	Yea K, Kim J, Yoon JH, et al: Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J Biol Chem. 284:33833–33840. 2009. View Article : Google Scholar : PubMed/NCBI
14	Fam BC, Rose LJ, Sgambellone R, et al: Normal muscle glucose uptake in mice deficient in muscle GLUT4. J Endocrinol. 214:313–327. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ha E, Bang JH, Son JN, et al: Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma. Mol Med Rep. 3:275–279. 2010.
16	Lautamäki R, Rönnemaa T, Huupponen R, et al: Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism. 56:881–886. 2007. View Article : Google Scholar : PubMed/NCBI
17	Apostolov EO, Shah SV, Ok E, et al: Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem. 51:719–728. 2005. View Article : Google Scholar : PubMed/NCBI
18	Apostolov EO, Ray D, Savenka AV, et al: Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol. 21:1852–1857. 2010. View Article : Google Scholar : PubMed/NCBI
19	Apostolov EO, Basnakian AG, Ok E and Shah SV: Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease. J Ren Nutr. 22:134–138. 2012. View Article : Google Scholar
20	Apostolov EO, Shah SV, Ok E and Basnakian AG: Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol. 27:826–832. 2007. View Article : Google Scholar : PubMed/NCBI
21	Asci G, Basci A, Shah SV, et al: Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology (Carlton). 13:480–486. 2008. View Article : Google Scholar
22	Apostolov EO, Shah SV, Ray D and Basnakian AG: Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol. 29:1622–1630. 2009. View Article : Google Scholar : PubMed/NCBI
23	Shiu SW, Xiao SM, Wong Y, et al: Carbamylation of LDL and its relationship with myeloperoxidase in type 2 diabetes mellitus. Clin Sci (Lond). 126:175–181. 2014. View Article : Google Scholar
24	Wallberg-Henriksson H and Zierath JR: GLUT4: a key player regulating glucose homeostasis? Insights from transgenic and knockout mice (review). Mol Membr Biol. 18:205–211. 2001. View Article : Google Scholar : PubMed/NCBI
25	Kapur S, Bedard S, Marcotte B, et al: Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes. 46:1691–1700. 1997. View Article : Google Scholar : PubMed/NCBI
26	Perreault M and Marette A: Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 7:1138–1143. 2001. View Article : Google Scholar : PubMed/NCBI
27	Charbonneau A and Marette A: Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins. Diabetes. 59:861–871. 2010. View Article : Google Scholar : PubMed/NCBI